Artivion Q2 revenue $113.0M (+15% YoY), net income $1.3M; raises FY 2025 guidance

ARTIVION, INC.

2025-Q2 EPS reported $0.02 revenue$211,950,000

Revenue $113.0M vs $98.0M YoY; GAAP net income $1.3M ($0.03 EPS) vs net loss $(2.1M) prior year.
Non-GAAP net income $10.7M ($0.24 EPS) vs $2.9M ($0.07) YoY; adjusted EBITDA $24.8M (+33%).
On-X +24%, stent grafts +24%, BioGlue +4%, Preservation +3% constant currency growth.
FY 2025 guidance raised: constant currency growth now 12-14%; reported revenue $435-443M.
Retired $99.5M of convertible notes; FDA IDE approved for Arcevo LSA pivotal trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.